CVR 33161395Public limited company (A/S)Engroshandel med medicinalvarer og sygeplejeartikler (464610)København SVFounded 15 Sep 2010
Employees
40
CVR registry, Aug 2026
0 (0%) over 12 months
Revenue
157.8M
DKK, annual report 2026
-28.1% on 2025
Result
+15.2M
DKK, annual report 2026
Equity
98.6M
DKK, annual report 2026
Compiled by Dandex from the Central Business Register (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish company data. Connect it once and ask about SPECIFIC PHARMA A/S, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set Up DandexNOMECO A/SCVR 20678232, 100% of capital and votes, since 15 Sep 2014
Uffe Kåre Jensensince 1 May 2019
CVR 20678232100% of capital and votessince 15 Sep 2014
Holders of 5% or more, from the owner register. CVR records shares in bands, not exact figures.
Ultimate controller
PHOENIX International Holdings GmbH
Holds 100% of capital and votes in PHOENIX DANISH HOLDING A/S, since 16 Nov 2012
Holding company
CVR 34702047Public limited company (A/S)
Holds 100% of capital and votes in NOMECO A/S, since 9 Jan 2013
Holding company
CVR 20678232Public limited company (A/S)
Holds 100% of capital and votes in SPECIFIC PHARMA A/S, since 15 Sep 2014
This company
SPECIFIC PHARMA A/S
CVR 33161395
CVR records founders at incorporation. It does not record whether they are alive or still involved.
16 Apr 2012 to 2 Nov 2026.
15 Sep 2010 to 2 Nov 2026.
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | 123,270 | 177,609 | 210,987 | 219,329 | 157,797 |
| Operating profit | +9,614 | +16,672 | +28,779 | +36,403 | +15,191 |
| Result for the year | +7,769 | +9,876 | +25,560 | +29,239 | +15,192 |
| Equity | 85,488 | 89,564 | 106,245 | 111,203 | 98,645 |
| Total assets | 103,079 | 104,981 | 126,169 | 134,475 | 115,179 |
| Employees (average) | 25 | 28 | 33 | 34 | 37 |
| Credit metrics (Dandex calculations) | |||||
| Revenue growth (omsætningsvækst) | -11.7% | 44.1% | 18.8% | 4% | -28.1% |
| EBIT margin (overskudsgrad) | 7.8% | 9.4% | 13.6% | 16.6% | 9.6% |
| EBITDA | 10,482 | 17,411 | 28,945 | 36,536 | 15,322 |
| EBITDA margin | 8.5% | 9.8% | 13.7% | 16.7% | 9.7% |
| Employee growth (vækst i antal ansatte) | 0% | 12% | 17.9% | 3% | 8.8% |
| Net interest-bearing debt (NIBD, nettorentebærende gæld) | 2,431 | 148 | 303 | 258 | 139 |
| Gearing, NIBD / EBITDA | 0.2x | 0x | 0x | 0x | 0x |
| ROIC (afkast af investeret kapital) | 8.3% | 14.6% | 22.9% | 26% | 11.3% |
| Capex (investeringer i anlægsaktiver) | 119note 1 | 87note 2 | 231note 2 | 75note 2 | 13note 2 |
| Capex % of sales (investeringer i procent af omsætningen) | 0.1%note 1 | 0.1%note 2 | 0.1%note 2 | 0%note 2 | 0%note 2 |
| NIBD incl. group and owner balances (NIBD inkl. koncern- og ejermellemværender) | -66,736 | -69,028 | -86,863 | -102,827 | -85,156 |
DKK thousands. Annual reports via XBRL. Employees are the annual report's average and may cover a group.
Credit metrics are Dandex calculations from the filed figures, not filed values; estimates are in grey with a note. Ratios are percentages and gearing a multiple. Definitions. No cash flow statement: included in the group's (ÅRL § 86, stk. 4).
Annual report 2026
1 Feb 2025 to 31 Jan 2026, published 26 Jun 2026
Annual report 2025
1 Feb 2024 to 31 Jan 2025, published 1 Jul 2025
Annual report 2024
1 Feb 2023 to 31 Jan 2024, published 28 Jun 2024
Annual report 2023
1 Feb 2022 to 31 Jan 2023, published 7 Jul 2023
Annual report 2022
1 Feb 2021 to 31 Jan 2022, published 6 Jul 2022
1 registered in CVR.
P-number 1016332409Borgmester Christiansens Gade 40, 2450 København SV
No other current company drawn.
